Author: Pandzic, Dragan ; Misic, Debora ; Petkovic Curcin, Aleksandra ; Jovic, Sasa ; Simonovic, Marko ; Stosic, Srboljub ; Kozomara, Ruzica ; Supic, Gordana ; Brkic, Marko

OBJECTIVEDespite advances in diagnosis and treatment in recent years, oral squamous cell carcinoma (OSCC) is still associated with a high recurrence rate and poor survival. MiR-196a2 and TLR2 have been implicated in cancer progression and prognosis, but the significance of their genetic variants in OSCC remains unelucidated.DESIGNThis study investigated the miR-196a2 rs11614913 and TLR2 rs5743708 genetic variants in Caucasian HPV-negative OSCC patients (n = 95) and age- and sex-matched healthy controls (n = 108) using real-time PCR. An assessment was conducted on their association with clinicopathological features, overall survival (OS), recurrence-free survival (RFS) and OSCC risk.RESULTSOSCC patients carrying the miR-196a2 rs11614913 TT genotype had a higher risk of tumor recurrence (P = 0.045) and shorter RFS (P = 0.041). The proportional hazards assumption was violated for tumor stage. Stage-stratified Kaplan-Meier analysis showed that miR-196a2 rs11614913 genotypes and combined CC+CT vs. TT variants significantly affected RFS in stage I/II OSCC patients (P = 0.012 and P = 0.003, respectively), but not in advanced stage III/IV patients (P = 0.545 and P = 0.287, respectively). Cox regression confirmed miR-196a2 rs11614913 as an independent predictor of RFS in early stage (HR=3.407, P = 0.015), but not in advance stage patients (HR=1.090, P = 0.711). No significant associations with OS were found. Additionally, the TLR2 rs5743708 variant allele A was significantly associated with a lower risk of OSCC (Adjusted OR=0.406, P = 0.013).CONCLUSIONSThese findings suggest that miR-196a2 rs11614913 could play a stage-dependent role in RFS, influencing early-stage OSCC but losing prognostic significance in advanced disease. Additionally, TLR2 rs5743708 may contribute to the decreased OSCC risk.

01 May 2025·Clinical Nutrition

Corrigendum to “Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey” Clin Nutr 2025 Feb 17:47:54–67

Author: Taus, Marina ; Aimasso, Umberto ; Schneider, Stéphane M ; Crivelli, Adriana ; Thibault, Ronan ; Livovsky, Dan M ; Martinuzzi, Andrés L N ; Gallitelli, Livia ; Rasmussen, Henrik H ; Kozjek, Nada Rotovnik ; Itzhaki, Moran Hellerman ; Boluda, Esther Ramos ; Pape, Ulrich-Frank ; Orlandoni, Paolo ; Gandullia, Paolo ; Krznaric, Zeljko ; Layec, Sabrina ; Santarpia, Lidia ; Sasdelli, Anna S ; Hütterer, Elisabeth ; Bergoin, Charlotte ; Poullenot, Florian ; Lamprecht, Georg ; Aguayo, Pilar Serrano ; Pironi, Loris ; Regano, Nunzia ; Lal, Simon ; Bueno, Marta ; Fehr, Rebecca ; Maíz-Jiménez, María ; Pelaez, Rosa Burgos ; Lezo, Antonella ; Vanuytsel, Tim ; Lopez-Urdiales, Rafael ; Chapman, Brooke ; Osland, Emma ; Zarpellon, Martina ; Carey, Sharon ; Martín, Cristina Campos ; Blüthner, Elizabeth ; Sobocki, Jacek ; Cuerda, Cristina ; Francini-Pesenti, Francesco ; Bezmarević, Mihailo ; Chen, Mona ; Joly, Francisca ; Ellegard, Lars ; Seguy, David ; Jezerski, Denise ; Martins da Rocha, Mariana Hollanda

01 Apr 2025·Clinical Nutrition

Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey

Article

Author: Taus, Marina ; Aimasso, Umberto ; Crivelli, Adriana ; Schneider, Stéphane M ; Thibault, Ronan ; Livovsky, Dan M ; Martinuzzi, Andrés L N ; Gallitelli, Livia ; Campos Martín, Cristina ; Rasmussen, Henrik H ; Kozjek, Nada Rotovnik ; Itzhaki, Moran Hellerman ; Pape, Ulrich-Frank ; Boluda, Esther Ramos ; Orlandoni, Paolo ; Gandullia, Paolo ; Krznaric, Zeljko ; Layec, Sabrina ; Santarpia, Lidia ; Sasdelli, Anna S ; Bergoin, Charlotte ; Hütterer, Elisabeth ; Poullenot, Florian ; Lamprecht, Georg ; Aguayo, Pilar Serrano ; Lal, Simon ; Regano, Nunzia ; Pironi, Loris ; Diez, Marta Bueno ; Fehr, Rebecca ; Maíz-Jiménez, María ; Pelaez, Rosa Burgos ; Lezo, Antonella ; Vanuytsel, Tim ; Lopez-Urdiales, Rafael ; Chapman, Brooke ; Osland, Emma ; Zarpellon, Martina ; Carey, Sharon ; Blüthner, Elizabeth ; Sobocki, Jacek ; Francini-Pesenti, Francesco ; Cuerda, Cristina ; Joly, Francisca ; Chen, Mona ; Bezmarević, Mihailo ; Ellegard, Lars ; Seguy, David ; Jezerski, Denise ; Martins da Rocha, Mariana Hollanda

BACKGROUND AND AIMTeduglutide is a glucagon-like peptide-2 analogue used to promote intestinal rehabilitation and decrease the dependence from intravenous supplementation (IVS) in patients with short bowel syndrome and intestinal failure (SBS-IF). The aim of this study was to gain a better understanding of international real-world Teduglutide use since its launch.METHODSData from an international multicenter database for chronic IF were analysed. All the adult patients with SBS-IF included by centers that treated at least one patient with Teduglutide during the study period (2015-2022) were investigated. The baseline characteristics and the outcome of patients treated with Teduglutide (n.269) were compared to those of patients not receiving the drug (Controls, n.3081). The center experience was categorized based on the number of patients treated with Teduglutide: <10 or ≥10.RESULTSTeduglutide cohort exhibited higher male prevalence, younger age, longer duration of HPN, higher percentage of SBS with jejunocolonic anastomosis, lower IVS volume, improved oral intake, and higher percentage of patients weaned from IVS. Controls showed higher percentages of patients deceased or lost to follow up. Centers with ≥10 patients treated with Teduglutide showed higher weaning rates and lower mortality rates.CONCLUSIONSThis is the largest analysis of Teduglutide's real-world setting in SBS-IF. Clinicians preferentially selected for treatment patients with better prognostic indicators. Outcomes were significantly better in centers with higher Teduglutide treatment volumes, emphasizing the need for specialized referral centers to optimize care for SBS-IF patients.

100 Deals associated with University of Defense

100 Translational Medicine associated with University of Defense

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 21 Jul 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

University of Defense

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 21 Jul 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing